I have developed new approaches to functional and anatomic magnetic resonance imaging for over 30 years. I’ve applied these methods to improve detection and accurate diagnosis of cancer, and monitor cancer response to therapy. I am the Director of Magnetic Resonance Imaging Research at the University of Chicago, and Co-Director of the Advanced Imaging Program of the University of Chicago Comprehensive Cancer center. I’ve collaborated with our outstanding mammographic group and medical physics colleagues for many years to build internationally recognized research program in quantitative breast cancer MR imaging – which parallels and compliments a leading clinical program in breast cancer diagnosis and management. Similarly, I’ve collaborated with Dr. Oto and others to develop a leading translational research program focused on improving prostate cancer screening with MRI, and using MRI to guide therapye. With these collaborators, I’ve made pioneering contributions to MRI methods that improve prostate and breast cancer diagnosis and treatment. My research includes use of pre-clinical methods for breast and prostate cancer to improve understanding of cancer biology and guide the development of improved clinical methods.
University of California at Berkeley
Berkeley, CA
Ph.D. - Physical Chemistry
1984
Reed College
Portland
B.A - Physical Chemistry
1977
Systematic evaluation of MRI-based characterization of tumor-associated vascular morphology and hemodynamics via a dynamic digital phantom.
Systematic evaluation of MRI-based characterization of tumor-associated vascular morphology and hemodynamics via a dynamic digital phantom. J Med Imaging (Bellingham). 2024 Mar; 11(2):024002.
PMID: 38463607
Self-supervised multicontrast super-resolution for diffusion-weighted prostate MRI.
Self-supervised multicontrast super-resolution for diffusion-weighted prostate MRI. Magn Reson Med. 2024 Feb 02.
PMID: 38308149
Prostate Cancers Invisible on Multiparametric MRI: Pathologic Features in Correlation with Whole-Mount Prostatectomy.
Prostate Cancers Invisible on Multiparametric MRI: Pathologic Features in Correlation with Whole-Mount Prostatectomy. Cancers (Basel). 2023 Dec 13; 15(24).
PMID: 38136370
Multi-model sequential analysis of MRI data for microstructure prediction in heterogeneous tissue.
Multi-model sequential analysis of MRI data for microstructure prediction in heterogeneous tissue. Sci Rep. 2023 10 01; 13(1):16486.
PMID: 37779137
Four-quadrant vector mapping of hybrid multidimensional MRI data for the diagnosis of prostate cancer.
Four-quadrant vector mapping of hybrid multidimensional MRI data for the diagnosis of prostate cancer. Med Phys. 2024 Mar; 51(3):2057-2065.
PMID: 37642562
Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer.
Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer. Magn Reson Imaging. 2023 Aug 21; 104:9-15.
PMID: 37611646
External Evaluation of a Mammography-based Deep Learning Model for Predicting Breast Cancer in an Ethnically Diverse Population.
External Evaluation of a Mammography-based Deep Learning Model for Predicting Breast Cancer in an Ethnically Diverse Population. Radiol Artif Intell. 2023 Nov; 5(6):e220299.
PMID: 38074785
Parametric maps of spatial two-tissue compartment model for prostate dynamic contrast enhanced MRI - comparison with the standard tofts model in the diagnosis of prostate cancer.
Parametric maps of spatial two-tissue compartment model for prostate dynamic contrast enhanced MRI - comparison with the standard tofts model in the diagnosis of prostate cancer. Phys Eng Sci Med. 2023 Sep; 46(3):1215-1226.
PMID: 37432557
Improving reader accuracy and specificity with the addition of hybrid multidimensional-MRI to multiparametric-MRI in diagnosing clinically significant prostate cancers.
Improving reader accuracy and specificity with the addition of hybrid multidimensional-MRI to multiparametric-MRI in diagnosing clinically significant prostate cancers. Abdom Radiol (NY). 2023 10; 48(10):3216-3228.
PMID: 37358605
Pharmacokinetic Analysis of Enhancement-Constrained Acceleration (ECA) reconstruction-based high temporal resolution breast DCE-MRI.
Pharmacokinetic Analysis of Enhancement-Constrained Acceleration (ECA) reconstruction-based high temporal resolution breast DCE-MRI. PLoS One. 2023; 18(6):e0286123.
PMID: 37319275